
Background Reliable biomarkers for predicting clinical outcomes in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) treated with immunotherapy remain limited. This study evaluated the association between longitudinal EBV DNA trajectories and clinical outcomes in patients with R/M NPC receiving immune checkpoint inhibitors.Methods This post hoc analysis used data from a multicenter, single-arm, Phase II trial evaluating the programmed cell death-ligand 1 (PD-L1) inhibitor KL-A167 in patients with previously treated R/M NPC. Plasma EBV DNA was measured at baseline and at each scheduled efficacy assessment, which was conducted every six weeks until disease progression. EBV DNA trajectories were distinguished through a logistic trajectory model. Multivariable Cox models were used to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for survival outcomes.Results We identified three distinct trajectories: persistently undetectable (n = 17, 13.8%), fluctuating (n = 40, 32.5%), and persistently detectable (n = 66, 53.7%). Compared with the persistently undetectable group, HRs of death were 4.96 (95% CI, 1.60-15.40) and 12.59 (95% CI, 4.01-39.51) for the fluctuating and persistently detectable groups, respectively. HRs of disease progression were 1.96 (95% CI, 0.97-3.96) and 3.22 (95% CI, 1.56-6.67), respectively.Conclusion This study suggests that plasma EBV DNA trajectories could be a promising biomarker for monitoring treatment response and longitudinal risk stratification.
Background TTMV-HPV DNA testing is prognostic during post-treatment surveillance of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), but the significance of testing before conventional 3-month response assessment remains unclear.Methods We retrospectively analyzed 332 patients across 8 US sites with biopsy-proven HPV-associated OPSCC who underwent initial definitive treatment and had >= 1 TTMV-HPV DNA test performed 1 to 89 days after treatment completion. Event-free survival (EFS) was evaluated using a 90-day landmark approach.Results The first TTMV-HPV DNA test obtained 1-89 days after treatment was negative in 310 patients (93%), indeterminate in 3 (1%), and positive in 19 (6%). Among 59 patients with repeat testing after an initially negative result, 57 (97%) remained negative and 2 (3%) converted to positive; both patients who converted subsequently developed recurrence. Of 13 patients with an initially positive result and sufficient follow-up for trajectory analysis, 6 (46%) subsequently resolved to negative and none developed recurrence, whereas 7 (54%) remained persistently positive and 6 (86%) developed recurrence. In a 90-day landmark analysis, the last early post-treatment TTMV-HV DNA result was associated with subsequent event-free survival.Conclusions TTMV-HPV DNA testing during the 1-89-day post-treatment interval was associated with subsequent clinical outcomes in HPV-associated OPSCC. Persistent positivity identified patients at increased risk, whereas positive results that resolved were not followed by recurrence in this cohort.
Background We performed an outcome-specific network meta-analysis comparing contemporary energy devices in thyroidectomy.Methods Randomized controlled trials comparing conventional hemostasis with Harmonic, LigaSure, Thunderbeat, or other advanced energy devices during thyroidectomy were included. Frequentist random-effects network meta-analyses were performed per outcome, with treatments ranked by P-scores and consistency assessed via design-by-treatment interaction and node-splitting analyses.Results Compared to conventional hemostasis, Harmonic significantly reduced operative time (SMD, -1.88), blood loss (SMD, -2.29), drainage volume (SMD, -1.77), hospital stay (SMD, -0.74), transient hypocalcemia (OR, 0.61), transient recurrent laryngeal nerve palsy (OR, 0.63), and postoperative bleeding (OR, 0.56). LigaSure improved operative efficiency but showed less consistent recovery and safety benefits. Harmonic ranked highest across most outcomes.Conclusions Harmonic showed the most favorable relative effects across the evaluated outcomes. However, these findings do not establish overall device superiority; selection should consider absolute benefits and device-specific characteristics.
Background: The aims of this study are: to assess the association of tumor budding (TB) and worst pattern of invasion (WPOI) with other clinical and histopathological prognostic factors of oral tongue and floor squamous cell carcinoma (OTFSSC), to evaluate their impact on survival outcomes and to assess whether they can be considered independent prognostic factors with respect to pathological depth of invasion (pDOI).Methods: A retrospective multicenter study was conducted on patients who underwent compartmental surgery for locally advanced OTFSCC.Results: A total of 134 patients were enrolled in the study. WPOI was found to be an independent negative prognostic factor for the risk of N+ at diagnosis. Patients with infiltrative WPOI presented a statistically significant increased risk of recurrence and loco-regional recurrence.Conclusions: TB and WPOI are promising prognostic markers in the therapeutic management of OTFSCC, potentially guiding possible treatment intensification.
Background This study evaluates relapse patterns and treatment outcomes in oral cavity carcinoma (OCC) patients treated with flap-sparing radiotherapy (RT).Methods Patients treated with surgery and immediate free-flap reconstruction followed by RT due to OCC between 2018 and 2024 were analyzed retrospectively. During target volume delineation, the high-risk clinical target volume (CTV) was the native tissue-flap interface with an additional isotropic margin of 10 mm. We estimated the cumulative incidence and geometric patterns of local failures.Results Thirty-four patients matched the inclusion criteria. Median follow-up was 44 months. Three patients experienced local recurrences. Two relapses occurred at the native tissue-flap junction, with no intraflap failure. Three cases of Grade 3 acute oral mucositis, two cases of late Grade 3 dysphagia, and two cases of osteoradionecrosis of the jaw were observed. Clinically significant flap-related complication was not reported.Conclusion No intra-flap local recurrence was observed after flap-sparing RT. The entire flap does not need to be intentionally covered in the CTV. Further investigation of planning optimization for the reconstructed flap is needed.